Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month Low – Time to Sell?

Royalty Pharma plc (NASDAQ:RPRX) hit a new 52-week low during trading on Tuesday . The company traded as low as $24.70 and last traded at $25.00, with a volume of 4385083 shares trading hands. The stock had previously closed at $24.84.

Analyst Ratings Changes

RPRX has been the topic of several analyst reports. Citigroup lowered their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, October 25th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Royalty Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $41.67.

Royalty Pharma Trading Down 2.6 %

The business has a 50 day moving average of $26.55 and a 200 day moving average of $27.19. The firm has a market capitalization of $14.42 billion, a price-to-earnings ratio of 12.68, a PEG ratio of 4.36 and a beta of 0.46. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th were given a dividend of $0.21 per share. The ex-dividend date was Friday, November 15th. This represents a $0.84 annualized dividend and a dividend yield of 3.43%. Royalty Pharma’s payout ratio is currently 43.52%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. increased its holdings in shares of Royalty Pharma by 5.0% in the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock worth $40,705,000 after acquiring an additional 70,130 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Royalty Pharma during the 3rd quarter worth approximately $61,000. Sanctuary Advisors LLC raised its holdings in Royalty Pharma by 78.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 41,466 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 18,288 shares during the period. Hohimer Wealth Management LLC lifted its stake in Royalty Pharma by 1.0% in the third quarter. Hohimer Wealth Management LLC now owns 145,357 shares of the biopharmaceutical company’s stock valued at $4,112,000 after buying an additional 1,445 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Royalty Pharma by 6.1% in the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock valued at $205,562,000 after buying an additional 417,490 shares during the period. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.